What is Clovis Oncology's stock symbol?
Clovis Oncology trades on the NASDAQ under the ticker symbol "CLVS."
Where is Clovis Oncology's stock going? Where will Clovis Oncology's stock price be in 2017?
12 brokerages have issued 12 month price objectives for Clovis Oncology's stock. Their forecasts range from $23.00 to $110.00. On average, they anticipate Clovis Oncology's share price to reach $61.92 in the next twelve months.
When will Clovis Oncology announce their earnings?
Clovis Oncology is scheduled to release their next quarterly earnings announcement on Wednesday, May, 3rd 2017.
What are analysts saying about Clovis Oncology stock?
Here are some recent quotes from research analysts about Clovis Oncology stock:
According to Zacks Investment Research, "Clovis got a huge boost with the FDA granting accelerated approval to its advanced ovarian cancer treatment, Rubraca. It is not only the first approved product in Clovis’ portfolio, but also has bright prospects given the immense commercial potential in the target market and the tremendous demand for PARP inhibitors. Successful commercialization will significantly boost Clovis’ top line, going forward. Rubraca is also under review in the EU for a comparable ovarian cancer indication. Several studies on Rubraca, targeting different types of ovarian cancer patients, are currently underway. Meanwhile, Clovis is looking to expand Rubraca’s label into additional indication like prostrate, breast and pancreatic cancers, among others. Also, shares of Clovis outperformed the industry in the past one year. Estimates have been stable ahead of Q4 results. However, Clovis’ dependence on Rubraca alone for growth is a cause for concern." (2/8/2017)
- Stifel Nicolaus analysts commented, "This price assumes about a 40% market share for rucaparib throughout addressable ovarian cancer (OC). However, in deriving this target, we include sales in the maintenance setting for ovarian cancer with a weighting of 75% (some risk remains to ARIEL3) and note that full weighing of this unapproved usage would suggest a fair value of about $104. Furthermore, inclusion of sales in mCRPC, which we consider highly promising but where large trials are just starting, suggests a fair value for Clovis shares of about $182. We consider most of the ongoing trials for rucaparib to be relatively low risk, but with several other players also competing for each indication we believe a takeout price of about 50% of our best case scenario makes sense." (1/23/2017)
J P Morgan Chase & Co analysts commented, "CLVS’ 2Q report this afternoon was fairly uneventful, though the co did note that rucaparib’s full NDA dataset had been accepted for presentation at ESMO (Oct 7- 11, Copenhagen), and that ARIEL3 data (rucap in maintenance) is now expected in 4Q17 following release of a similar data set from TSRO (though CLVS has no knowledge of the event rate in ARIEL3). While we do see potential value for rucap, we think it’s hard to differentiate between the PARPs at this stage, and we are maintaining our Neutral rating." (8/9/2016)
Piper Jaffray Companies analysts commented, "We are assuming coverage of Clovis Oncology with a Neutral rating and an $18 PT ($28 prior) as we do not have enough confidence ahead of a key binary event (rociletinib ODAC/ PDUFA) to justify a more constructive outlook at this time. With the updated rociletinib efficacy data falling short of AstraZeneca’s Tagrisso, we struggle to see a clear regulatory and commercial path forward and are remaining on the sidelines. Behind rociletinib, the company’s PARP inhibitor, rucaparib, has demonstrated early signs of clinical benefit, but again runs into an AZN drug already approved with a similar mechanism (Lynparza), and we are not convinced that rucaparib has demonstrated clear differentiation in what looks like a small and crowded market. In sum, CLVS is a player in the attractive area of targeted oncology therapy and we view CLVS’ risk/reward profile at current levels as sufficiently balanced given the uncertainty with rociletinib and competitive landscape with rucaparib. • Rociletinib path uncertain: The deterioration in objective response rate (ORR) last fall (~60% to 32% at the 625 mg dose) casts doubt on the approvability and commercial opportunity in the absence of a meaningful point of differentiation with AstraZeneca’s Tagrisso, which has been FDA approved and rapidly incorporated into NCCN guidelines for treatment of T790M+ patients with NSCLC. Even if CLVS is able to convince ODAC next week and the FDA that the appropriate comparator is chemotherapy given the accelerated approval of Tagrisso, we struggle to see a meaningful commercial opportunity in T790M positive patients. That said, the opportunity for rociletinib in T790M negative patients may ultimately prove attractive; rociletinib has shown a confirmed ORR of 29% in this patient population (n = 24). In addition, combination studies with checkpoint inhibitors are commencing. • Rucaparib active, but in a crowded field: CLVS is currently completing a rolling NDA submission (expected in Q2) for PARP inhibitor rucaparib in ovarian cancer patients who have received 3 or more lines of therapy, and approval may occur by YE. Rucaparib has demonstrated activity in both early lines of therapy as well as heavily pre-treated patients, though with small numbers, patient selection / heterogeneity combined with a highly competitive landscape, rucaparib’s profile is not differentiated yet, in our view. CLVS is advancing rucaparib in patients with "BRCA-like" tumor signatures as well as prostate cancer and beyond, and we await further details on the profile in these patients. • What could change? Although we remain Neutral on the shares given the NT uncertainty with rociletinib and crowded PARP field, Clovis’ cash reserves (~$528M YE15), organization and CEO with a long term track record of creating value keep us watching closely for opportunities to become constructive. RISKS TO ACHIEVEMENT OF PRICE TARGET Rociletinib and rucaparib may fail/succeed in its trials or fail to/gain regulatory approval COMPANY DESCRIPTION Clovis is a drug developer for oncology pursuing three small-molecule candidates. Page 1 of 79 Clovis Oncology, Inc. Piper Jaffray does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decisions. This report should be read in conjunction with important disclosure information, including an attestation under Regulation Analyst certification, found on pages 78 – 79 of this report or at the following site: http://www.piperjaffray.com/researchdisclosures.Page 2 of 79 Clovis Oncology, Inc.Page 3 of 79 Clovis Oncology, Inc.Page 4 of 79 Clovis Oncology, Inc.•" (4/5/2016)
Who owns Clovis Oncology stock?
Clovis Oncology's stock is owned by many different of retail and institutional investors. Top institutional investors include Palo Alto Investors LLC (9.86%), Patrick Lee, MD (9.86%), Integrated Core Strategies (US) LLC (5.10%), State Street Corp (5.55%), Boxer Capital LLC (2.20%) and Franklin Resources Inc. (1.47%). Company insiders that own Clovis Oncology stock include Erle T Mast, Gillian C Ivers-Read, James C Blair, Lindsey Rolfe and M James Barrett.
Who sold Clovis Oncology stock? Who is selling Clovis Oncology stock?
Clovis Oncology's stock was sold by a variety of institutional investors in the last quarter, including Boxer Capital LLC, FMR LLC, Marshall Wace LLP, Frontier Wealth Management LLC, Columbia Wanger Asset Management LLC and Clough Capital Partners L P.
Who bought Clovis Oncology stock? Who is buying Clovis Oncology stock?
Clovis Oncology's stock was acquired by a variety of institutional investors in the last quarter, including State Street Corp, Perceptive Advisors LLC, Renaissance Technologies LLC, Royce & Associates LP, Guggenheim Capital LLC, Fred Alger Management Inc., Franklin Resources Inc. and Artal Group S.A..
How do I buy Clovis Oncology stock?
Shares of Clovis Oncology can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Clovis Oncology stock cost?
One share of Clovis Oncology stock can currently be purchased for approximately $57.90.